文献速递前列腺癌

血浆雄激素受体与多西他赛治疗转移性去势抵抗性前列腺癌

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
PubMed 文献 · Eur Urol · 2018-10-26

本研究汇总分析163例多西他赛治疗的转移性去势抵抗性前列腺癌(mCRPC)患者,血浆雄激素受体(AR)增益者总生存(OS)显著缩短(HR=1.61,95%CI 1.08-2.39,p=0.018),但无进展生存(PFS)和PSA应答率无显著差异。探索性分析显示,AR正常患者接受阿比特龙/恩扎卢胺的OS优于多西他赛(HR=1.93,95%CI 1.19-3.12,p=0.008),AR增益患者多西他赛有获益趋势(HR=0.53,95%CI 0.24-1.16,p=0.11)。作者建议AR正常者应接受阿比特龙/恩扎卢胺,AR增益者可获益于多西他赛,此选择需前瞻性随机试验评估。

要点

  • 多西他赛治疗mCRPC中,血浆AR增益与更短OS相关(HR=1.61,95%CI 1.08-2.39,p=0.018)。
  • AR增益与PFS(HR=1.04,95%CI 0.74-1.46,p=0.8)及PSA应答(OR=1.14,95%CI 0.65-1.99,p=0.7)无显著关联。
  • 探索性分析:AR正常者阿比特龙/恩扎卢胺OS更优(HR=1.93,95%CI 1.19-3.12,p=0.008),AR增益者多西他赛有获益趋势(HR=0.53,95%CI 0.24-1.16,p=0.11)。

核心结论

  • 数据提示AR正常患者应接受阿比特龙/恩扎卢胺,AR增益者可获益于多西他赛,此治疗选择需前瞻性随机试验评估。

研究设计与样本

  • 多机构 pooled analysis,采用微滴式数字PCR检测治疗前血浆样本AR状态。
  • 评估163例多西他赛治疗患者血浆AR与OS/PFS及PSA应答率关联。
  • 整合既往73例未化疗阿比特龙/恩扎卢胺治疗患者更新数据与115例一线多西他赛患者数据进行探索性分析。

主要发现

  • 多西他赛治疗患者中,AR增益者OS显著缩短(HR=1.61,95%CI 1.08-2.39,p=0.018)。
  • AR增益与PFS无显著关联(HR=1.04,95%CI 0.74-1.46,p=0.8)。
  • AR增益与PSA应答无显著关联(OR=1.14,95%CI 0.65-1.99,p=0.7)。
  • 一线治疗探索性分析中,血浆AR与多西他赛 vs 阿比特龙/恩扎卢胺对OS存在显著交互作用(HR=0.16,95%CI 0.06-0.46,p<0.001)。
  • 对PFS也存在显著交互作用(HR=0.31,95%CI 0.12-0.80,p=0.02)。

临床怎么用

  • 作者认为AR正常患者应接受阿比特龙/恩扎卢胺,AR增益者可获益于多西他赛。
  • 作者指出该治疗选择需前瞻性随机试验评估。

局限性

  • 探索性分析中AR增益患者多西他赛获益的置信区间宽(HR=0.53,95%CI 0.24-1.16,p=0.11)。
  • 作者指出该治疗选择需前瞻性随机试验评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Plasma androgen receptor (AR) gain identifies metastatic castration-resistant prostate cancer (mCRPC) patients with worse outcome on abiraterone/enzalutamide, but its relevance in the context of taxane chemotherapy is unknown. We aimed to evaluate whether docetaxel is active regardless of plasma AR and to perform an exploratory analysis to compare docetaxel with abiraterone/enzalutamide. This multi-institutional study was a pooled analysis of AR status, determined by droplet digital polymerase chain reaction, on pretreatment plasma samples. We evaluated associations between plasma AR and overall/progression-free survival (OS/PFS) and prostate-specific antigen (PSA) response rate in 163 docetaxel-treated patients. OS was significantly shorter in case of AR gain (hazard ratio [HR]=1.61, 95% confidence interval [CI]=1.08-2.39, p=0.018), but not PFS (HR=1.04, 95% CI 0.74-1.46, p=0.8) or PSA response (odds ratio=1.14, 95% CI=0.65-1.99, p=0.7). We investigated the interaction between plasma AR and treatment type after incorporating updated data from our prior study of 73 chemotherapy-naïve, abiraterone/enzalutamide-treated patients, with data from 115 first-line docetaxel patients. In an exploratory analysis of mCRPC patients receiving first-line therapies, a significant interaction was observed between plasma AR and docetaxel versus abiraterone/enzalutamide for OS (HR=0.16, 95% CI=0.06-0.46, p<0.001) and PFS (HR=0.31, 95% CI=0.12-0.80, p=0.02). Specifically, we reported a significant difference for OS favoring abiraterone/enzalutamide for AR-normal patients (HR=1.93, 95% CI=1.19-3.12, p=0.008) and a suggestion favoring docetaxel for AR-gained patients (HR=0.53, 95% CI=0.24-1.16, p=0.11). These data suggest that AR-normal patients should receive abiraterone/enzalutamide and AR-gained could benefit from docetaxel. This treatment selection merits prospective evaluation in a randomized trial. PATIENT SUMMARY: We investigated whether plasma androgen receptor (AR) predicted outcome in metastatic castration-resistant prostate cancer (mCRPC) patients treated with docetaxel, and we performed an exploratory analysis in patients treated with docetaxel or AR-directed drugs as first-line mCRPC therapy. We showed that plasma AR normal favored hormonal treatment, whilst plasma AR-gained patients may have had a longer response to docetaxel, suggesting that plasma AR status could be a useful treatment selection biomarker.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Conteduca V, Jayaram A, Romero-Laorden N, et al. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2018. PMID: 30773204. doi:10.1016/j.eururo.2018.09.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。